{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-233500","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.462878+00:00","generated_at":"2026-06-10T21:07:48.858151+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Viridian Therapeutics CFO Kristian Humer resigns; Seth Harmon appointed principal financial officer","bullets":["Kristian Humer, CFO and CBO, resigns effective Sept 12, 2023; eligible for severance under existing agreement.","Seth Harmon, SVP of Finance (joined May 2023), assumes role of principal financial and accounting officer.","Harmon's base salary increased to $410,000; entitled to 12-month severance upon involuntary termination.","Harmon previously CFO of BioNTech US subsidiary and held finance roles at Neon Therapeutics and Merrimack.","Harmon is a CPA with prior experience at Ernst & Young."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-233500","json":"https://secwatch.observer/filing/0001193125-23-233500.json","markdown":"https://secwatch.observer/filing/0001193125-23-233500.md","text":"https://secwatch.observer/filing/0001193125-23-233500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/d638217d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:07:48.858151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4440805f7","claim":"Kristian Humer resigned as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On September 8, 2023, Kristian Humer, the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics, Inc. (the “Company”), resigned, effective September 12, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"f9df007dc6","claim":"Seth Harmon changed role as principal financial and accounting officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"on September 12, 2023, Seth Harmon, the Company’s Senior Vice President of Finance, assumed the role of the Company’s principal financial and accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed the role"},{"label":"Role","value":"principal financial and accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}